Pneumococcal Conjugate Vaccine clinical trials
How each study uses Pneumococcal Conjugate Vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Pneumococcal Conjugate Vaccine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2012 | 1 |
| 2016 | 2 |
| 2018 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 7
Pfizer (2) · H. Lee Moffitt Cancer Center and Research Institute (1) · London School of Hygiene and Tropical Medicine (1) · Henry M. Jackson Foundation for the Advancement of Military Medicine (1) · Sanofi Pasteur, a Sanofi Company (1) · University Hospital, Montpellier (1) · Merck Sharp & Dohme LLC (1) · LG Life Sciences (1)
Often tested with
Tested in the same studies.
Pneumococcal Vaccines (2) · 13-valent pneumococcal vaccine (1)
Studies
Open first, then newest update. How each study uses Pneumococcal Conjugate Vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Opportunistic Pneumococcal Immunisation Trial in MALnutritionRecruitingPhase 4Nick FancourtNCT06817421Written as Pneumococcal conjugate vaccine
- Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T TherapyActive, not recruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT04745559Written as Pneumococcal conjugate vaccine (PCV13)
- Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine BoostingCompletedPhase 3Henry M. Jackson Foundation for the Advancement of Military MedicineNCT00622843Written as pneumococcal conjugate vaccine
- Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced PeopleActive, not recruitingPhase 4London School of Hygiene and Tropical MedicineNCT04945681Written as Pneumococcal conjugate vaccine
- Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)CompletedPhase 1Sanofi Pasteur, a Sanofi CompanyNCT06698198Written as Pneumococcal Conjugate Vaccine
- Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis PatientsCompletedNot applicableUniversity Hospital, MontpellierNCT02547493Written as pneumococcal conjugate vaccine
- Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy InfantsTerminatedPhase 2PfizerNCT03550313Written as Multivalent
- Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy InfantsCompletedPhase 2PfizerNCT03512288Written as Multivalent
- The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)CompletedPhase 2Merck Sharp & Dohme LLCNCT01513551Written as Pneumococcal Conjugate Vaccine (V114)
- A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in AdultsCompletedPhase 1LG Life SciencesNCT02892812Written as Pneumococcal conjugate vaccine
- Evaluation of the Immunogenicity and Reactogenicity of a Pneumococcal Conjugate Vaccine in Healthy AdultsCompletedPhase 2Public Health EnglandNCT00197821Written as pneumococcal conjugate vaccine
- Targeting of Immune Response After Pneumococcal VaccinationCompletedPhase 4Helsinki University Central HospitalNCT01402245Written as pneumococcal conjugate vaccine
Given beside what is tested · 1 — Pneumococcal Conjugate Vaccine is usual care or a partner of the new treatment
As the comparator · 3 — what is tested is compared with Pneumococcal Conjugate Vaccine
- Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)CompletedPhase 1PT Bio FarmaNCT03109600Written as Pneumococcal conjugate vaccine
- Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and InfantsCompletedPhase 2NovartisNCT01229176Written as Pneumococcal conjugate vaccine
- Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and InfantsCompletedPhase 2NovartisNCT01437267Written as Pneumococcal conjugate vaccine